Form 4: Gilead Sciences CFO Sells 8,500 Shares Under 10b5-1 Trading Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 8,500 shares of common stock at $91.96 per share, according to a recent SEC filing.

Summary

• Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, sold 8,500 shares of the company's common stock.
• The sale occurred on December 16, 2024, at a price of $91.96 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
• Following the sale, Dickinson directly owns 132,373 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for a stock sale under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

Executive stock sales are a common occurrence and are often part of pre-planned trading strategies. This sale by the CFO is not unusual and is within the bounds of regulatory compliance.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among corporate executives to avoid accusations of insider trading.
• Many executives at comparable companies such as Amgen, AbbVie, and Regeneron also utilize these plans for stock transactions.
• The volume of shares sold is relatively small compared to the total outstanding shares of Gilead Sciences, and is not unusual for a CFO.

Stakeholder Impact

• The stock sale by the CFO is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Gilead Sciences, Andrew D. Dickinson, CFO, stock sale, Rule 10b5-1, insider trading, GILD